Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study

Abstract Background Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant prostate cancer (CRP...

Full description

Bibliographic Details
Main Authors: Anniina Hyväkkä, Okko‐Sakari Kääriäinen, Tapio Utriainen, Eliisa Löyttyniemi, Kalle Mattila, Petri Reinikainen, Jorma Sormunen, Minna Jääskeläinen, Päivi Auvinen, Heikki Minn, Maria Sundvall
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
bone metastases
castration‐resistant prostate cancer
radium‐233 (Ra‐223) therapy
real‐world evidence
Online Access:https://doi.org/10.1002/cam4.5262

Internet

https://doi.org/10.1002/cam4.5262

Similar Items